Compare LNG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNG | NNVC |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5B | 35.2M |
| IPO Year | 1996 | 2008 |
| Metric | LNG | NNVC |
|---|---|---|
| Price | $272.03 | $1.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 2 |
| Target Price | ★ $310.19 | $6.00 |
| AVG Volume (30 Days) | ★ 1.9M | 601.5K |
| Earning Date | 11-05-2026 | 09-28-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ 69.93 | 34.92 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,976,000,000.00 | N/A |
| Revenue This Year | $17.13 | N/A |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.21 | N/A |
| 52 Week Low | $186.20 | $0.85 |
| 52 Week High | $300.94 | $2.23 |
| Indicator | LNG | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 46.97 |
| Support Level | $264.36 | $1.21 |
| Resistance Level | $277.78 | $1.38 |
| Average True Range (ATR) | 6.33 | 0.15 |
| MACD | -1.07 | 0.00 |
| Stochastic Oscillator | 23.86 | 36.31 |
Cheniere Energy is a liquefied natural gas producer with two facilities in Corpus Christi, Texas, and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.